These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22398807)

  • 21. Progesterone receptor in estrogen receptor-positive breast cancer: the association between HER-2 and lymph node involvement is age related.
    Neven P; Pochet N; Drijkoningen M; Amant F; De Smet F; Paridaens R; Christiaens MR; Vergote I
    J Clin Oncol; 2006 Jun; 24(16):2595; author reply 2595-7. PubMed ID: 16735717
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparison of clinicopathologic characteristics and prognosis of triple-negative with Her-2-overexpressing breast cancer].
    Wang YJ; Wang N; Wang B; Qin WX; Xue CY
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):346-50. PubMed ID: 19799082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches for triple-negative breast cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999
    [No Abstract]   [Full Text] [Related]  

  • 25. Estrogen receptor-beta status influences clinical outcome of triple-negative breast cancer.
    Sakamoto G; Honma N
    Breast Cancer; 2009; 16(4):281-2. PubMed ID: 19387776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

  • 27. The sensitivity and specificity of estrogen receptor, progesterone receptor and HER-2 staining in core biopsies of invasive breast carcinomas.
    Frederik P; Cecile C; Tjalma WA
    Breast J; 2007; 13(4):436-7. PubMed ID: 17593058
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and biological characteristics of breast cancer.
    Kocic B; Filipovic S; Petrovic B; Mijalkovic D; Rancic N; Poultsidi A
    J BUON; 2010; 15(4):660-7. PubMed ID: 21229626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-negative breast cancer: what the radiologist needs to know.
    Whitman GJ; Albarracin CT; Gonzalez-Angulo AM
    Semin Roentgenol; 2011 Jan; 46(1):26-39. PubMed ID: 21134526
    [No Abstract]   [Full Text] [Related]  

  • 31. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy.
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1095-101. PubMed ID: 20638197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
    Altundag K; Bulut N; Sari E; Harputluoglu H
    Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
    [No Abstract]   [Full Text] [Related]  

  • 36. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic importance of triple negative breast carcinoma.
    Mersin H; Yildirim E; Berberoglu U; Gülben K
    Breast; 2008 Aug; 17(4):341-6. PubMed ID: 18450442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Practice and consideration on neoadjuvant therapy for early breast cancer].
    Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.